Research and analysis

Mycoplasma genitalium antimicrobial resistance surveillance (MARS)

Data on the latest findings relating to antimicrobial resistance in Mycoplasma genitalium from specimens collected in sexual health clinics across England.

From:
Public Health England
Published
20 November 2020
Last updated
19 August 2021 — See all updates

Documents

MARS pilot report: data to March 2020

Ref: PHE publications gateway number: GOV-9299

PDF, 1.22 MB, 29 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

MARS pilot report: data to March 2019

Ref: PHE publications gateway number: GW-1722

PDF, 1.05 MB, 28 pages

Details

Surveillance of antimicrobial resistance is critical in guiding national management guidelines to ensure appropriate treatment.

The M. genitalium Antimicrobial Resistance Surveillance (MARS) pilot was established to assess the feasibility of conducting sentinel surveillance of antimicrobial resistance in M. genitalium from specimens collected in sentinel sexual health clinics across England. Subsequent survey rounds and continued M. genitalium surveillance through MARS will provide a rich resource for informing future updates to management guidelines in the UK.

For queries relating to MARS, please contact: grasp.enquiries@phe.gov.uk

Cases of treatment failure to second-line therapeutics, such as moxifloxacin, should be reported to Public Health England (PHE) using the HIV and STI web portal

Published 20 November 2020
Last updated 19 August 2021 + show all updates

  1. Added MARS pilot report: data to March 2020.

  2. First published.

Related content